Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Epidermolysis Bullosa Dystrophica 1Cytopenia 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory 1Adenocarcinoma 1

Interventions

AP 1903 reagent 3cedazuridine 1ON 01910 1Interleukin-8 1HuMax-IL8 1Decitabine 1DNA 1Cord Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cytopenia × ON 01910 × Clear all
NCT00854945 2017-06-26

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Traws Pharma, Inc.

Phase 1/2 Completed
36 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡